26 enrolling by invitation. 26 Phase 2, 6 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Enrolling by invitation 26 |
| Phase 1 | 6 | Enrolling by invitation 6 |
| Phase 3 | 4 | Enrolling by invitation 4 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome Biocidin REMOVE, Placebo - Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | Phase 2 | Enrolling by invitation | Johns Hopkins University | 40 | 2026-10-26 | 2026-11-03 |
| Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer MRG003 (Becotatug Vedotin) - Biliary Tract Neoplasms | Phase 2 | Enrolling by invitation | Jiangmen Central Hospital | 30 | 2026-09-22 | 2026-10-26 |
| Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma Hypofractionated Radiation Therapy - Anal Cancer | Phase 2 | Enrolling by invitation | University of Vermont Medical Center | 24 | 2026-08-26 | 2026-09-15 |
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis Low molecular weight fucoidan and standard care, Placebo and standard of care - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Enrolling by invitation | Allama Iqbal Medical College | 90 | 2026-08-01 | 2026-08-26 |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD SPY001, SPY002, SPY003 - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Enrolling by invitation | Spyre Therapeutics, Inc. | 645 | 2026-06-08 | 2026-11-03 |
| Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined. Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Enrolling by invitation | Black Tie Medical, Inc. | 50 | 2026-04-30 | 2026-04-27 |
| Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction laparoscopic and endoscopic cooperative surgery - Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Enrolling by invitation | Peking University People's Hospital | 40 | 2026-04-01 | 2026-04-30 |
| Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg - Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer | Phase 2 | Enrolling by invitation | Hoag Memorial Hospital Presbyterian | 39 | 2026-03-05 | 2026-09-23 |
| Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma Nimotuzumab, camrelizumab, Albumin paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | Peking University | 48 | 2025-11-01 | 2025-12-31 |
| Patients With High-grade Pancreatic Neuroendocrine Tumors Lurbinectedin 4 MG Injection [Zepzelca] - Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors | Phase 2 | Enrolling by invitation | National Cancer Center, Korea | 46 | 2025-09-23 | 2025-10-01 |
| Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy - Colorectal Cancer, Gastric Cancer | Phase 2 | Enrolling by invitation | Blokhin's Russian Cancer Research Center | 128 | 2025-06-03 | 2026-04-24 |
| XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI - Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | Phase 1 / Phase 2 | Enrolling by invitation | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-05-23 | 2026-09-25 |
| Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer Treatment :Gemcitabine plus Nab-Paclitaxel (AG regimen) in combination with Iparomlimab and Tuvorili - Gallbladder Cancer Unresectable | Phase 2 | Enrolling by invitation | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 44 | 2025-05-01 | 2025-12-30 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum - Probiotics, Gastrointestinal Diseases | Phase 2 | Enrolling by invitation | National Institute of Pediatrics, Mexico | 120 | 2025-02-01 | 2025-03-14 |
| Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1 - Gallbladder Cancer and Extrahepatic Cholangiocarcinoma | Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Zhengzhou University | 50 | 2024-11-08 | 2025-03-30 |
| A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics Prednisone, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Phase 2 / Phase 3 | Enrolling by invitation | Han Ying | 244 | 2024-10-30 | 2026-10-29 |
| Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum budesonide, omeprazole (proton pump inhibitor) - Crohn Disease (CD) | Phase 2 / Phase 3 | Enrolling by invitation | Medical University of Warsaw | 114 | 2024-07-30 | 2024-12-06 |
| Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT) Gemcitabine nab-PaclitaxelLenvatinibTislelizumab - Gallbladder Cancer, Cholangiocarcinoma | Phase 2 | Enrolling by invitation | Wei Gong | 44 | 2024-06-01 | 2025-05-08 |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Man Hu | 100 | 2024-03-30 | 2025-03-30 |
Showing 20 of 26. Sign in to see all of them.
Colitis, Ulcerative (3) · Gallbladder Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Cholangiocarcinoma (2) · Colitis (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Adenoma, Islet Cell (1) · Anus Neoplasms (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1)
Neoplasms (17) · Digestive System Neoplasms (15) · Gastrointestinal Diseases (15) · Neoplasms by Site (15) · Neoplasms by Histologic Type (10) · Gastrointestinal Neoplasms (8) · Intestinal Diseases (8) · Neoplasms, Glandular and Epithelial (8) · Carcinoma (6) · Colonic Diseases (6) · Biliary Tract Diseases (5) · Esophageal Diseases (5) · Gastroenteritis (5) · Head and Neck Neoplasms (4)
130-nm albumin-bound paclitaxel (2) · Fecal Microbiota Transplantation (2) · camrelizumab (2) · (4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone (1) · Alginates (1) · Anti-Inflammatory Agents (1) · Bevacizumab (1) · Budesonide (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Folfox protocol (1) · Immunomodulation (1) · Injections (1) · Laparoscopy (1)
Abbisko Therapeutics Co, Ltd (1) · Allama Iqbal Medical College (1) · Black Tie Medical, Inc. (1) · Blokhin's Russian Cancer Research Center (1) · Disc Medicine, Inc (1) · Han Ying (1) · Hoag Memorial Hospital Presbyterian (1) · Jiangmen Central Hospital (1) · Johns Hopkins University (1) · Man Hu (1) · Medical University of Warsaw (1) · National Cancer Center, Korea (1) · National Institute of Pediatrics, Mexico (1) · Peking University (1) · Peking University People's Hospital (1)
China (12) · United States (6) · South Korea (3) · Australia (2) · Belgium (2) · Germany (2) · Italy (2) · Mexico (2) · Poland (2) · Taiwan (2) · Argentina (1) · Austria (1) · Brazil (1) · Chile (1) · Czechia (1)
Carlos Becerra, MD (1) · Christopher L Anker, MD (1) · Gerry Mullin, MD (1) · Man Hu, Dr. (1) · Rozina Shahadat Khan, MBBS, M.PHIL,MSPH, CHPE,PHDHND (1) · Sara Espinosa-Padilla, Ph.D. (1) · Wei Gong (1) · Wei-Fen Xie (1) · Will Savage, MD PhD (1) · Yi-Sheng Chou, M.D (1) · Zhihao MM Lu, PHD (1)
PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 24891990, PMID 25040088, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 38291578, PMID 38713298, PMID 9718381
2025 (1)